iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Conditions: KRAS NP_004976.2:p.G12D; Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8
Interventions: Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Sponsors: M.D. Anderson Cancer Center
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 9, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments